Spotlight
Clinical Focus
Video Series
News
CME/CE
Partners
How Similar are Biosimilars? A look into the Future with Biosimilars in Multiple Sclerosis : Episode 11
Concluding Thoughts on Biosimilars in Multiple Sclerosis
Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share their advice for facilitating uptake of biosimilars in clinical practices.
EP: 1.What is a Biosimilar?
EP: 2.Comparison of Biosimilar Products and Reference Products
EP: 3.Approval Process for Biosimilars
EP: 4.Immunogenicity of Biosimilars
EP: 5.Cost Savings with Biosimilars and Use in Multiple Sclerosis
EP: 6.Natalizumab Biosimilar in Development in Multiple Sclerosis
EP: 7.Comparison of AFFIRM (Reference Natalizumab) and Antelope (Biosimilar Natalizumab) Trials
EP: 8.Access to and Challenges to Biosimilar use in Clinical Practice
EP: 9.Implementing Biosimilars in Clinical Practice
EP: 10.Biosimilar Discussion With Patients and Biosimilar Resources
Now Viewing
EP: 11.Concluding Thoughts on Biosimilars in Multiple Sclerosis
Related Videos
Related Content
